RDD Blog » biotechnology

R&D Directions Insider

‘Breakthrough’ startups reap investments from new early-stage fund

Wednesday, January 25th, 2012

Cambridge, Mass.-based Flagship Ventures recently launched the company's largest fund to date, raising $270 million for its life sciences funds, money that will add around 20 new biotechnology companies to Flagship's portfolio, according to officials. With the closing of the new fund, the company now has ...

Posted in Uncategorized, drug discovery | No Comments »

Biotech startup continues hot streak

Tuesday, January 10th, 2012

If you have been following some of the buzz out of the JP Morgan Healthcare Conference this week, access to traditionalÂ venture capital remains difficult for biomedical companies, particularly for biotech startups. Thus, opportunities to forge licensing agreements or corporate partnerships with large biopharma companies has become increasingly vital for startups ...

Posted in Uncategorized, drug discovery | No Comments »

Tool addresses biologic registration limits

Friday, May 7th, 2010

Scientific software company Accelrys Inc. recently unveiled the worldâ€™s first multi-entity, production-ready biologics registration system. Developed from a three-year collaboration withÂ drugmakers including Abbott and Merck & Co., the data tool is designed to helpÂ companies overcome the historically difficult IT challenges associated with registering and defining complex biological materials. Accelrys' database ...

Posted in antibodies, drug discovery | No Comments »

Dual-filing feat a rarity for little guy

Wednesday, February 17th, 2010

You may have read recently about a small biotech outfit in New Jersey having successfully submitted simultaneous regulatory filings in the United States and Europe for Luveniq, a new oral treatment for non-infectious uveitis, an inflammatory condition of the eye that can lead to blindness (see the release here). You ...

Posted in Uncategorized, clinical trials, filed for approval | No Comments »

©2012 UBM Canon